According to Exact Sciences's latest financial reports the company has a price-to-book ratio of 3.93.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2022-12-31 | 2.89 | -27.55% |
2021-12-31 | 3.99 | -43.47% |
2020-12-31 | 7.06 | 18.3% |
2019-12-31 | 5.97 | -47.73% |
2018-12-31 | 11.4 | -5.56% |
2017-12-31 | 12.1 | 179.83% |
2016-12-31 | 4.32 | 58.23% |
2015-12-31 | 2.73 | -67.56% |
2014-12-31 | 8.42 | 36.36% |
2013-12-31 | 6.17 | -10.1% |
2012-12-31 | 6.86 | 33.36% |
2011-12-31 | 5.15 | 31.61% |
2010-12-31 | 3.91 | -80.21% |
2009-12-31 | 19.8 | -409.56% |
2008-12-31 | -6.38 | -145.93% |
2007-12-31 | 13.9 | 174.32% |
2006-12-31 | 5.07 | 113.5% |
2005-12-31 | 2.37 | -10.47% |
2004-12-31 | 2.65 | -83.41% |
2003-12-31 | 16.0 | 196.69% |
2002-12-31 | 5.39 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
![]() Sanofi SNY | 1.72 | -56.29% | ๐ซ๐ท France |
![]() Veracyte VCYT | 1.52 | -61.36% | ๐บ๐ธ USA |
![]() Myriad Genetics MYGN | 1.78 | -54.64% | ๐บ๐ธ USA |
![]() Biocept
BIOC | 0.2786 | -92.91% | ๐บ๐ธ USA |